Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced two key appointments to its founding executive team. Ash Jayagopal, Ph.D., has joined the company as Chief Scientific Officer (CSO) and Joe Schachle...
Before joining ValGenesis, Mike served as the Chief Product & Technology Officer of Intelex Technologies and currently serves as a growth advisor for multiple startups.
Consistent with BioMarin's regular planning, Dr. Bernstein will succeed Geoff Nichol M.B. Ch.B., MBA, FRACP, who has served for almost five years making significant contributions to the Company's clinical development program including three product approvals. Dr. Nichol will remain at the Company to assist with the transition and to serve in an advisory capacity on late stage clinical programs.
Genprex Appoints Mark S. Berger, M.D. as CMO & Hemant Kumar, Ph.D. as Chief Manufacturing & Technology Officer
“It is my privilege and pleasure to welcome Mark and Hemant to our management team. Their collective accomplishments and deep domain expertise in clinical development and gene therapy manufacturing, respectively, will be of great value as they help guide Genprex and advance our important Acclaim-1 and Acclaim-2 clinical trials in non-small cell lung cancer this year,” stated Mr. Varner, Chief Executive Officer.
“The addition of Sarah as a Scientific Co-Founder will further accelerate our existing groundbreaking work in the field of Condensomics™ and the build-out of our capabilities,” said Kelly Martin, Executive Chairman and a Founder of the Company.
Francesco Maria Lavino, CEO of F2G Ltd, added: "Camilla's experience and successful track record in rare diseases will be invaluable as we look to maximise the potential of olorofim.
Ruth McKernan, newly appointed Chair added: “The formation of Cumulus Neuroscience represents a significant opportunity to address some of the current limitations of clinical trials in dementia and other brain disorders.
Chip Clark, Genocea’s President, and Chief Executive Officer said, "As we advance our pipeline, including GEN-011, our neoantigen-targeted T cell therapy for the treatment of solid tumors, we believe Jennifer’s deep industry and commercial expertise will prove invaluable to us."
“As Aadi prepares for the potential commercialization of its investigational candidate, nanoparticle albumin-bound mTOR inhibitor, FYARRO™ (sirolimus albumin-bound nanoparticles for injectable suspension, nab-sirolimus ABI-009) for PEComa, and advances its registrational trial in patients harboring TSC1 and TSC2 inactivating alterations, the addition of Emma’s expertise in transitioning and growing a newly public oncology company will be invaluable to Aadi and her appointment will complement our recently appointed Board," said Caley Castelein, M.D., Aadi Board Chairman.
Dr. Hall’s drug-development experience will help advance AltruBio’s pipeline of biologic therapies through clinical-testing for treatment of patients with immunological disease.
“Patrick is a proven corporate development leader with a strong track record of success in executing strategic transactions, as well as developing and implementing corporate and business unit strategies across a variety of therapeutic area franchises,” said Nick Colangelo, President and Chief Executive Officer of Vericel.
The three new members of the SAB are Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD, and Dr. Stéphane Champiat MD, Ph.D.